Claims for Patent: 5,212,081
✉ Email this page to a colleague
Summary for Patent: 5,212,081
Title: | Stabilization of polypeptide fragments against proteolytic degradation |
Abstract: | Enzyme-donor fragments and other unstructured peptides are stabilized against proteolytic degradation by including a mixture of soluble, random-sequence peptides in the assay medium or in the medium in which the enzyme-donor fragment or other peptide is stored. |
Inventor(s): | Coty; Bill (Danville, CA), Khanna; Pyare (Fremont, CA) |
Assignee: | Microgenics Corporation (Concord, CA) |
Application Number: | 07/503,836 |
Patent Claims: | 1. A method of stabilizing a beta-galactosidase enzyme-donor fragment in a complementation assay which comprises:
including in an assay medium in which said assay is carried out a mixture of soluble, random-sequence peptides, wherein said mixture comprises a hydrolysate of bovine serum albumin or human serum proteins, in an amount sufficient to reduce proteolytic degradation of said enzyme-donor fragment. 2. A composition for stabilizing an enzyme-donor fragment form beta-galactosidase against proteolytic degradation in a complementation assay, which comprises a solution containing said enzyme-donor fragment and a mixture of soluble, random-sequence peptides, herein said mixture comprises a hydrolysate of bovine serum albumin or human serum proteins, in an amount sufficient to stabilize said fragment against proteolysis when said composition is added to a serum sample. 3. The composition of claim 2, wherein said peptides and said fragment are present at a weight ratio of at least 10:1. 4. A method of stabilizing a biologically active, linear peptide substantially without secondary structure against proteolytic degradation, which comprises: including in a medium which contains said active peptide and in which said proteolytic cleavage occurs a mixture of soluble, random-sequence peptides, wherein said mixture comprises a hydrolysate of bovine serum albumin or human serum proteins, in an amount sufficient to reduce proteolysis of said active peptide. |
Details for Patent 5,212,081
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Grifols Therapeutics Llc | ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 | albumin (human) | For Injection | 101138 | 10/21/1942 | ⤷ Try a Trial | 2040-01-28 |
Baxalta Us Inc. | BUMINATE, FLEXBUMIN | albumin (human) | Injection | 101452 | 03/03/1954 | ⤷ Try a Trial | 2040-01-28 |
Csl Behring Ag | ALBURX | albumin (human) | Injection | 102366 | 07/23/1976 | ⤷ Try a Trial | 2040-01-28 |
Grifols Biologicals Llc | ALBUTEIN | albumin (human) | Injection | 102478 | 08/15/1978 | ⤷ Try a Trial | 2040-01-28 |
Instituto Grifols, S.a. | HUMAN ALBUMIN GRIFOLS | albumin (human) | Injection | 103352 | 02/17/1995 | ⤷ Try a Trial | 2040-01-28 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.